{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:12:38Z","timestamp":1785784358889,"version":"3.56.0"},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T00:00:00Z","timestamp":1385942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0080060","type":"journal-article","created":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T16:15:25Z","timestamp":1386000925000},"page":"e80060","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":53,"title":["Characterization and Drug Resistance Patterns of Ewing's Sarcoma Family Tumor Cell Lines"],"prefix":"10.1371","volume":"8","author":[{"given":"William A.","family":"May","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita S.","family":"Grigoryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Keshelava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Cabral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Jenabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Triche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Patrick","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,12,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(09)70286-4","article-title":"Ewing&apos;s sarcoma","volume":"11","author":"NJ Balamuth","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/jcp.56.2.96","article-title":"Ewing&apos;s sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities","volume":"56","author":"SA Burchill","year":"2003","journal-title":"J Clin Pathol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/mpo.10240","article-title":"Treatment of Ewing sarcoma family of tumors: current status and outlook for the future","volume":"40","author":"C Rodriguez-Galindo","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1038\/sj.onc.1204598","article-title":"Biology of EWS\/ETS fusions in Ewing&apos;s family tumors","volume":"20","author":"A Arvand","year":"2001","journal-title":"Oncogene"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2005.08.007","article-title":"EWS-ETS oncoproteins: the linchpins of Ewing tumors","volume":"363","author":"R Janknecht","year":"2005","journal-title":"Gene"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1038\/onc.2010.205","article-title":"Recent advances in the molecular pathogenesis of Ewing&apos;s sarcoma","volume":"29","author":"EC Toomey","year":"2010","journal-title":"Oncogene"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1158\/0008-5472.CAN-04-2463","article-title":"An expression signature classifies chemotherapy-resistant pediatric osteosarcoma","volume":"65","author":"MB Mintz","year":"2005","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q","article-title":"Prognostic impact of P53 status in Ewing sarcoma","volume":"89","author":"E de Alava","year":"2000","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/hupa.2002.31475","article-title":"Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing&apos;s sarcoma: correlation with clinical outcome","volume":"33","author":"G Amir","year":"2002","journal-title":"Hum Pathol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/sj.bjc.6690190","article-title":"Overexpression of p53 protein in primary Ewing&apos;s sarcoma of bone: relationship to tumour stage, response and prognosis","volume":"79","author":"A Abudu","year":"1999","journal-title":"Br J Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.22908","article-title":"Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis","volume":"110","author":"K Honoki","year":"2007","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/JCO.2005.02.081","article-title":"Ewing sarcomas with p53 mutation or p16\/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse","volume":"23","author":"HY Huang","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M","article-title":"Prognostic impact of INK4A deletion in Ewing sarcoma","volume":"89","author":"G Wei","year":"2000","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00019606-199802000-00006","article-title":"Molecular diagnosis of Ewing tumors: improved detection of EWS-FLI-1 and EWS-ERG chimeric transcripts and rapid determination of exon combinations","volume":"7","author":"VS Meier","year":"1998","journal-title":"Diagn Mol Pathol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/sj.onc.1210991","article-title":"The EWS\/FLI1 oncogenic transcription factor deregulates GLI1","volume":"27","author":"JP Zwerner","year":"2008","journal-title":"Oncogene"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.onc.1204197","article-title":"Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas","volume":"20","author":"M Labuhn","year":"2001","journal-title":"Oncogene"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/51.5.1417","article-title":"In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors","volume":"51","author":"DJ Giard","year":"1973","journal-title":"J Natl Cancer Inst"},{"key":"ref18","first-page":"2643","article-title":"Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture","volume":"33","author":"JL Biedler","year":"1973","journal-title":"Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0165-4608(02)00670-2","article-title":"Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques","volume":"141","author":"A Martinez-Ramirez","year":"2003","journal-title":"Cancer Genet Cytogenet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0165-4608(86)90001-4","article-title":"Cytogenetic characterization of selected small round cell tumors of childhood","volume":"21","author":"J Whang-Peng","year":"1986","journal-title":"Cancer Genetics and Cytogenetics"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM198408303110907","article-title":"Chromosome translocation in peripheral neuroepithelioma","volume":"311","author":"J Whang-Peng","year":"1984","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1158\/0008-5472.CAN-04-0377","article-title":"Fenretinide cytotoxicity for Ewing&apos;s sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators","volume":"64","author":"S Batra","year":"2004","journal-title":"Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jsb.2006.12.012","article-title":"Multifocal two-photon laser scanning microscopy combined with photo-activatable GFP for in vivo monitoring of intracellular protein dynamics in real time","volume":"158","author":"J Martini","year":"2007","journal-title":"J Struct Biol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1535-7163.MCT-04-0331","article-title":"A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations","volume":"6","author":"T Frgala","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"ref25","first-page":"139","article-title":"DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy","volume":"110","author":"N Keshelava","year":"2005","journal-title":"Methods Mol Med"},{"key":"ref26","first-page":"473","article-title":"Allele frequencies for 15 short tandem repeat loci in representative sample of Croatian population","volume":"48","author":"P Projic","year":"2007","journal-title":"Croat Med J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrc2091","article-title":"The impact of translocations and gene fusions on cancer causation","volume":"7","author":"F Mitelman","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1996.14.4.1245","article-title":"Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?","volume":"14","author":"A Zoubek","year":"1996","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.1998.16.4.1248","article-title":"EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing&apos;s sarcoma","volume":"16","author":"E de Alava","year":"1998","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/labinvest.3780194","article-title":"Variability in gene expression patterns of Ewing tumor cell lines differing in EWS-FLI1 fusion type","volume":"80","author":"DN Aryee","year":"2000","journal-title":"Lab Invest"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0002-9440(10)64953-X","article-title":"Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing&apos;s sarcoma","volume":"156","author":"E de Alava","year":"2000","journal-title":"Am J Pathol"},{"key":"ref32","first-page":"1428","article-title":"Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing&apos;s sarcoma","volume":"59","author":"PP Lin","year":"1999","journal-title":"Cancer Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1200\/JCO.2009.24.5845","article-title":"Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children&apos;s Oncology Group","volume":"28","author":"JA van Doorninck","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.1999.17.6.1809","article-title":"EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing&apos;s sarcoma","volume":"17","author":"JP Ginsberg","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1073\/pnas.121616198","article-title":"Short tandem repeat profiling provides an international reference standard for human cell lines","volume":"98","author":"JR Masters","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cancergencyto.2004.08.023","article-title":"SKY and genetic fingerprinting reveal a cross-contamination of the putative normal colon epithelial cell line NCOL-1","volume":"158","author":"R Melcher","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0165-4608(99)00255-1","article-title":"Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma","volume":"120","author":"T Tsuchiya","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1038\/sj.onc.1201397","article-title":"Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors","volume":"15","author":"H Kovar","year":"1997","journal-title":"Oncogene"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1097\/00000478-200012000-00010","article-title":"Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing&apos;s sarcoma\/primitive neuroectodermal tumor","volume":"24","author":"AL Folpe","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"ref40","first-page":"1","article-title":"Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines","volume":"45","author":"N Keshelava","year":"2000","journal-title":"Cancer ChemotherPharmacol"},{"key":"ref41","first-page":"5396","article-title":"Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy","volume":"58","author":"N Keshelava","year":"1998","journal-title":"Cancer Res"},{"key":"ref42","first-page":"3551","article-title":"Pharmacokinetics of vincristine sulfate in adult cancer patients","volume":"41","author":"VS Sethi","year":"1981","journal-title":"Cancer Res"},{"key":"ref43","first-page":"2723","article-title":"Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial","volume":"47","author":"RF Struck","year":"1987","journal-title":"Cancer Res"},{"key":"ref44","first-page":"1952","article-title":"Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer","volume":"47","author":"CL Bennett","year":"1987","journal-title":"Cancer Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.1995.13.12.2954","article-title":"Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation?","volume":"13","author":"J Boos","year":"1995","journal-title":"J Clin Oncol"},{"key":"ref46","first-page":"813","article-title":"Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan","volume":"6","author":"MK Ma","year":"2000","journal-title":"Clin Cancer Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00043426-199611000-00004","article-title":"Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study","volume":"18","author":"DG Tubergen","year":"1996","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref48","first-page":"198","article-title":"Chronopharmacokinetic of a 48-hr continuous infusion of doxorubicin to children with acute lymphoblastic leukemia","volume":"34","author":"R Sabbagh","year":"1993","journal-title":"Proc Am Assoc Cancer Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00254536","article-title":"Pharmacokinetics of VP16-213 given by different administration methods","volume":"7","author":"M D'Incalci","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1200\/JCO.1996.14.5.1504","article-title":"Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia","volume":"14","author":"WL Furman","year":"1996","journal-title":"J Clin Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00280-010-1541-4","article-title":"Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases","volume":"68","author":"R Guilhaumou","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/0091270008325928","article-title":"Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children&apos;s Oncology Group","volume":"49","author":"JS McCune","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/1097-0142(19940215)73:4<1297::AID-CNCR2820730427>3.0.CO;2-#","article-title":"A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group","volume":"73","author":"LJ Ettinger","year":"1994","journal-title":"Cancer"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/pbc.20107","article-title":"Carboplatin-based chemotherapy for refractory and recurrent Ewing&apos;s tumours","volume":"43","author":"JS Whelan","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/pbc.20820","article-title":"Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial","volume":"47","author":"C Juergens","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/pbc.21182","article-title":"Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors","volume":"49","author":"MJ Burke","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/pbc.21140","article-title":"Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?","volume":"49","author":"N Al-Faris","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1023\/A:1026539908115","article-title":"Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria","volume":"11","author":"S Burdach","year":"2000","journal-title":"Ann Oncol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2006.05.7059","article-title":"Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l&apos;Enfant","volume":"24","author":"O Oberlin","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/pbc.21238","article-title":"Therapy for metastatic ESFT: is it time to ask new questions?","volume":"49","author":"KM Snyder","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2006-01-023101","article-title":"Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children&apos;s Oncology Group","volume":"109","author":"S Bhatia","year":"2007","journal-title":"Blood"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/pbc.21078","article-title":"The pediatric preclinical testing program: description of models and early testing results","volume":"49","author":"PJ Houghton","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/pbc.22801","article-title":"National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing","volume":"56","author":"MH Kang","year":"2011","journal-title":"Pediatr Blood Cancer"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0080060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T12:09:15Z","timestamp":1540296555000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0080060"}},"subtitle":[],"editor":[{"given":"Javier S.","family":"Castresana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,2]]},"references-count":63,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0080060","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,2]]}}}